BRCA2 and ovarian cancer: We recommend this patient be referred to the BCCA Hereditary Cancer Program.” The emphasis on HGSC patients resulted from the fact that studies done with central expert pathology review report that 95–100% of ovarian cancer patients with germline BRCA1 or BRCA2 mutations had invasive serous ovarian carcinomas, in studies where there was central pathology review using current diagnostic criteria [10, 20, 21].